Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats - Test2 - elhamkhani - TriplyDB

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

http://www.wikidata.org/entity/Q24619854

about

Posttranslational Modifications and the Immunogenicity of Biotherapeutics In vitro and in vivo modifications of recombinant and human IgG antibodies Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development Recombinant deamidated mutants of Erwinia chrysanthemi L-asparaginase have similar or increased activity compared to wild-type enzyme.Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media.Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies.Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.Analytical methods for physicochemical characterization of antibody drug conjugates Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Drug development: longer-lived proteins.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry.Post-translational structural modifications of immunoglobulin G and their effect on biological activity.Assessments of antibody biodistribution.Tailoring recombinant protein quality by rational media design.Characterization of human hybrid cell line, F2N78, through a comparison of culture performances and protein qualities.Effect of copper variation in yeast hydrolysate on C-terminal lysine levels of a monoclonal antibody.The molecular weight and concentration of dextran sulfate affect cell growth and antibody production in CHO cell cultures.Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes?New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry.Quick generation of Raman spectroscopy based in-process glucose control to influence biopharmaceutical protein product quality during mammalian cell culture.Screening and assessment of performance and molecule quality attributes of industrial cell lines across different fed-batch systems.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.Development of at-line assay to monitor charge variants of MAbs during production.

P2860

Q26748614-236C7BB0-09C0-4388-B969-3D5E33EE4F43 Q26859713-DAD326E3-DC5F-4CCC-B08E-ADDE2DF8FA45 Q28082880-3956199C-E9BB-4A0B-94B9-B16F9AF92514 Q30362969-2AB44864-40D8-43BE-B1D6-A1395A30A775 Q30377369-B6217294-283F-44D8-9F52-5B74420E6B1B Q31150455-C60AC272-ACA7-48D8-A09E-F9DCE1B96B93 Q34275537-61D5E655-1B0E-49AA-B2AD-191725E0A696 Q34909445-247B78A6-BA9C-4C97-B1C5-D78EDFB04D52 Q35032702-A666BA1D-1ABF-440B-B510-0E1967532E11 Q35624029-8FD9CFC8-257F-48D2-88BA-45F1ACBFB3D9 Q35961353-A95BC106-DD29-4E0B-A09F-4C8E35FC3C73 Q36211427-D6E041B8-00E9-4D7F-B356-814143999462 Q36213182-8E40F8A1-149F-4EBF-BEC1-A9B257E5DFE3 Q36402682-8A589AE6-4FC1-4AC8-AF4E-F38F0DC50216 Q37137948-077E96CB-687C-4DC4-B6D1-882A868CF51D Q37141605-4D5AAB93-B32E-4274-ADA6-445DCF1199B0 Q37567087-BC6AF74E-C40D-47B1-9AD1-681725C446A4 Q37703405-7C595ECA-CFA3-4A44-89BB-4B9D6CD63D39 Q37858385-4A3AAB4B-5805-41E6-8369-FF12532AC1CA Q37976121-D7357155-8F84-4BD7-9A57-CD04839E833B Q37981866-E3BD4394-0E9A-4D22-BB96-2C31A72EC533 Q37999739-01C51EE8-069D-4EC9-91DD-20E81EA90270 Q38072598-D34BBD71-640B-4401-9D52-1EC9D09E6586 Q38221786-DC2B6A05-01B8-4C5B-9A77-FFC2BF59DCE6 Q38246996-4E1715B9-CE91-469B-9DCF-F6325AB46F32 Q38364460-D2CD0343-5E37-4E55-8AC7-10BAF36F86DB Q38416739-BF81C4C9-8632-4EAD-85BD-D3A72AEDDC2D Q38722894-333144B6-6297-4EC4-A003-986F6A4ADFA2 Q38730325-8DA4EA79-3060-4148-8821-724C9F8733AC Q38739041-FE79CCF0-865F-4284-A576-2FFB5E293638 Q38740314-6654D852-9A70-4D96-B884-A65FCF08B1D9 Q38759336-A2C54BA3-D5C5-4951-A3BB-0D7A8EC0020F Q38759624-3F019463-6C84-49FC-B067-BA248062F5E3 Q38812885-E9C68102-7510-451A-800E-892E0997CBBA Q38818101-A7FCE600-E2E8-48B8-84EE-4A17706AD0D0 Q38826159-89ABEBCD-692F-4586-A91E-D7AB4ED16E22 Q38831148-D310DF5A-7E5A-48A0-B8D4-A54B49A11FA9 Q38875063-DAE94DF3-AD14-40BC-81DB-3C948A4FF5DC Q39020483-B3F8DCB0-7A45-44B0-9C5A-15AB0FA9014B Q39037926-95602FBD-04CC-4B06-A32F-F5A0121F646D

P2860

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

http://www.wikidata.org/entity/Q24619854

description

2010 nî lūn-bûn

@nan

2010 թուականին հրատարակուած գիտական յօդուած

@hyw

2010 թվականին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@ast

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@en

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@nl

type

label

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@ast

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@en

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@nl

prefLabel

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@ast

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@en

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@nl

P1433

Q24619854-6BA0EB81-AA3D-4A98-BE7C-F0741CFBF200

P1476

Q24619854-45E2D0F8-C608-4D8B-8363-3F167C8D9881

P2093

Q24619854-1C6545CF-7B59-4EAD-A81F-3085D3D3B96F

Q24619854-1DECDA46-4330-4553-856D-3942622524FF

Q24619854-22F7FE90-2DD9-487D-9C06-8975FB61BB20

Q24619854-2520DAF0-DA95-4D20-9433-F5A6BD9CAC16

Q24619854-2A3E2593-F86E-4883-BE50-C67355F90825

Q24619854-307FBF35-2A44-4A12-8BDE-79658990ADCA

Q24619854-4A14A541-8C68-4D1D-B072-8A6B73B57986

Q24619854-78F64785-0505-427F-AF0E-E8680DBA4220

Q24619854-7E433811-3459-4594-BA38-885A9E7D944D

Q24619854-87CCE443-311A-4A76-9E43-A30848162243

P2860

Q24619854-069B7541-E4AA-4197-9485-14923E79BECF

Q24619854-06EE4F71-69C9-41F8-A89C-55977AF3DE86

Q24619854-09CA17E2-F77B-4F78-BD98-6F66BC59A8D4

Q24619854-0E22343F-346C-4CDC-BB85-501008E78190

Q24619854-10C2688B-E8D0-4239-8815-E9B266F52591

Q24619854-1B33858B-0EB7-478F-9991-1D283AF0C5DA

Q24619854-1C400895-B4C5-4627-9FA4-8BC923D8BAD2

Q24619854-1CDFF04D-5CA4-437A-BE96-43E837188993

Q24619854-1DF1D2AE-2465-4186-B3BA-41FDE2858D02

Q24619854-1F0934CE-BED0-49FA-BAC7-9F46A27C353C

P304

Q24619854-8500C0EC-2CE6-4B03-89CE-0D677FA9CDA7

P31

Q24619854-0BCD12C1-65A8-4EC3-BBB8-7CA98101024D

P3181

Q24619854-D4E63989-7891-4D88-8647-6862217D5B34

P356

Q24619854-E2F9574B-28E3-4E2D-9C9E-DC01492F03D1

P407

Q24619854-9B6B4948-5B91-4858-B2A4-9999C13CAAAC

P433

Q24619854-99F6E427-233B-4C66-AB51-418C811E072D

P478

Q24619854-1F417679-8467-43FF-B3E5-46BCF4DCF33B

P577

Q24619854-429C5C2F-E649-44C7-AD21-F0F51CCAE3B1

P5875

Q24619854-0D1FBACE-2DDC-4C42-A701-950463FD3429

P698

Q24619854-45B6DA7D-4B2B-4C0C-8FD3-383E70860C22

P921

Q24619854-EAFB8E65-2D52-4094-BBB2-93CBAA9D4724

P932

Q24619854-D991B115-B539-4237-9E36-EE241B647173

P3181

P356

P1433

Monoclonal Antibodies

P1476

Charge variants in IgG1: Isola ...... s and pharmacokinetics in rats

@en

P2093

Alavattam Sreedhara

http://www.w3.org/2001/XMLSchema#string

Amita Joshi

http://www.w3.org/2001/XMLSchema#string

Cynthia Quan

http://www.w3.org/2001/XMLSchema#string

David E Allison

http://www.w3.org/2001/XMLSchema#string

Devin Tesar

http://www.w3.org/2001/XMLSchema#string

Ihsan Nijem

http://www.w3.org/2001/XMLSchema#string

Jihong Yang

http://www.w3.org/2001/XMLSchema#string

Leslie A Khawli

http://www.w3.org/2001/XMLSchema#string

Paul Motchnik

http://www.w3.org/2001/XMLSchema#string

Pin Yee Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Charge density-dependent strength of hydration and biological structure.

Improving the efficacy of antibody-based cancer therapies

Microlymphatics and lymph flow

Pressure effects on intra- and intermolecular interactions within proteins.

Characterizing biological products and assessing comparability following manufacturing changes.

Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.

Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

P304

613-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

860574

http://www.w3.org/2001/XMLSchema#string

P356

10.4161/MABS.2.6.13333

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46149539

http://www.w3.org/2001/XMLSchema#string

P698

20818176

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

3011216

http://www.w3.org/2001/XMLSchema#string